The FDA's April 30, 2026 proposal to exclude semaglutide from the 503B bulk substances list - currently in public comment through June 29, 2026 - would, if finalized, close large-scale outsourcing-facility compounding of semaglutide from bulk entirely
Serious adverse events occurred at similar rates in the treatment and placebo groups
Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
they are only produced in Japan
South Park first debuted on Comedy Central in 1997 and has been renewed through 2027
